IceCure Medical (ICCM) Common Equity (2020 - 2026)

IceCure Medical (ICCM) has reported Common Equity for 7 consecutive years, with $11.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity rose 311.48% year-over-year to $11.9 million in Q2 2026; TTM through Jun 2026 was $11.9 million, a 311.48% increase from a year earlier, with the FY2025 full-year figure at $9.1 million, up 31.15% from the prior year.
• Common Equity was $11.9 million for Q2 2026 at IceCure Medical, up from $8.5 million in the prior quarter.
• Over five years, Common Equity peaked at $25.4 million in Q4 2022 and troughed at $2.9 million in Q2 2025.
• A 5-year average of $13.2 million and a median of $11.8 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 72.75% in 2025 and surged 311.48% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $25.4 million in 2022, then sank by 52.16% to $12.2 million in 2023, then slumped by 43.26% to $6.9 million in 2024, then soared by 31.15% to $9.1 million in 2025, then jumped by 31.43% to $11.9 million in 2026.
• The last three Common Equity figures came in at $11.9 million (Q2 2026), $8.5 million (Q1 2026), and $9.1 million (Q4 2025), per Business Quant data.